Teriflunomide inhibits the de novo synthesis of pyrimidine in lymphocytes by suppressing dihydroorotate dehydrogenase (DHODH).

1、 Drug name

Terflunomide, trade name AUBAGIO.

2、 Indications

Used to treat adult relapsing multiple sclerosis (MS), including clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease.

3、 Specifications and characteristics

14 milligrams tablets, each containing 14 milligrams of Teriflunomide.

4、 Main components

Each active ingredient is teriflunomide.

5、 Usage and dosage

1. Conventional dosage: Recommended once daily, oral administration of 7mg or 14mg, with a fixed daily intake time.

2. Usage: It can be taken with meals or on an empty stomach, and food has no significant effect on the efficacy of the medication.

6、 Dose adjustment

1. Missed dose: If you miss the daily dose, you should skip this session and take the regular dose at the normal time the next day. Do not take twice the dose on the same day.

2. Vomiting: If vomiting occurs after taking medication, it should be considered as a missed dose and no additional dosage should be added.

3. Special population: prohibited for individuals with liver dysfunction; Patients with renal dysfunction (including severe cases) do not need to adjust the dosage.

7、 Medication precautions

1. Liver function monitoring: ALT levels should be monitored at least monthly within 6 months before treatment and after the start of treatment.

2. Pregnancy taboos: Pregnant women are prohibited from using it. Men and women of childbearing age should use effective contraceptive measures, and continue to use contraception after discontinuing the medication until the blood drug concentration is confirmed to be below 0.02 milligrams per liter through accelerated elimination procedures.

3. Infection risk: During treatment, there may be an increased risk of infection (including tuberculosis), and immediate medical attention is required if symptoms of infection appear.

4. Drug interactions: It is necessary to monitor and adjust the dosage of certain drugs (such as warfarin, oral contraceptives, rosuvastatin, etc.).

8、 Medication for special populations

1. Pregnant women: contraindicated use, there is a risk of fetal malformation.

2. Breastfeeding women: Prohibited, may pose a risk to the baby.

3. Children: Safety and efficacy have not been established, and pediatric trials have reported a risk of pancreatitis.

4. Elderly: Clinical studies did not include patients aged 65 and above.

9、 Adverse reactions

1. Common adverse reactions (incidence ≥ 10% and higher than placebo group ≥ 2%) include headache, diarrhea, nausea, hair loss, and elevated ALT levels.

2. Serious adverse reactions include: liver damage, infection, allergic reactions, severe skin reactions, peripheral neuropathy, hypertension, respiratory problems, etc.

10、 Contraindications

1. Severe liver dysfunction.

2. Pregnant women and women of childbearing age who have not used effective contraceptive measures.

3. Allergic to any excipients in Teriflunomide, Leflunomide, or AUBAGIO.

4. I am currently taking Leflunomide.

11、 Drug interactions

1. Affects CYP2C8 substrates (such as regorazine): may increase exposure.

2. Impact of warfarin: may reduce INR peak.

3. Impact on oral contraceptives: may increase exposure to estrogen and progesterone.

4. Affects CYP1A2 substrates (such as theophylline): may reduce exposure.

5. Affects OAT3 substrates (such as methotrexate): may increase exposure.

6. Affects BCRP and OATP1B1/1B3 substrates: such as rosuvastatin, the dose should not exceed 10 milligrams per day.

12、 Storage method

Suggested storage temperature is between 20 ° C and 25 ° C, with allowance for fluctuations between 15 ° C and 30 ° C.

Teriflunomideinformation